CNS metastases in breast cancer.

As systemic therapy of metastatic breast cancer improves, CNS involvement is becoming a more widespread problem. This article summarizes the current knowledge regarding the incidence, clinical presentation, diagnosis, prognosis, and treatment of CNS metastases in patients with breast cancer. When available, studies specific to breast cancer are presented; in studies in which many solid tumors were evaluated together, the proportion of patients with breast cancer is noted. On the basis of data from randomized trials and retrospective series, neurosurgery and stereotactic radiosurgery (SRS) may prolong survival in patients with single brain metastases. The treatment of multiple metastases remains controversial, as does the routine use of whole-brain radiotherapy (WBRT) after either surgery or SRS. Although it is widely assumed that chemotherapy is of limited benefit, data from case series and case reports suggest otherwise. WBRT, neurosurgery, SRS, and medical therapy each have a role in the treatment of CNS metastases; however, neurologic symptoms frequently are not fully reversible, even with appropriate therapy. Studies specifically targeted toward this group of patients are needed.

[1]  H. Bozcuk,et al.  Durable remission of leptomeningeal metastasis of breast cancer with letrozole: a case report and implications of biomarkers on treatment selection. , 2003, Japanese journal of clinical oncology.

[2]  J. Posner,et al.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients , 1982, Cancer.

[3]  G. Duncan,et al.  A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis , 1996, Cancer.

[4]  L. Schuchter Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Antonadou,et al.  Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Piccart,et al.  Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Wen,et al.  The treatment of recurrent brain metastases with stereotactic radiosurgery. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Levendag,et al.  Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. , 1999, International journal of radiation oncology, biology, physics.

[9]  A. Gabizon,et al.  Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. , 1995, Journal of neurosurgery.

[10]  W. Boogerd,et al.  Response of leptomeningeal metastases from breast cancer to hormonal therapy , 2000, Neurology.

[11]  R. Semrau,et al.  Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine , 2002, Journal of Cancer Research and Clinical Oncology.

[12]  F. Landoni,et al.  Complete remission of brain metastases from ovarian carcinoma with carboplatin. , 1998, European journal of obstetrics, gynecology, and reproductive biology.

[13]  A. Howell,et al.  Idarubicin and cyclophosphamide--an active oral chemotherapy regimen for advanced breast cancer. , 2000, Critical reviews in oncology/hematology.

[14]  E. Winer,et al.  Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma , 2003, Cancer.

[15]  A. Santini,et al.  Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. , 1996, Oncology.

[16]  Michael L. Wang,et al.  Capecitabine for 5‐Fluorouracil‐Resistant Brain Metastases From Breast Cancer , 2001, American journal of clinical oncology.

[17]  L. Recht,et al.  Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine , 2001, British Journal of Cancer.

[18]  E. Noordijk,et al.  The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. , 1994, International journal of radiation oncology, biology, physics.

[19]  W. Shapiro,et al.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. , 1975, The New England journal of medicine.

[20]  G. Hutchins,et al.  Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. , 1984, The American journal of medicine.

[21]  W. Boogerd,et al.  Acute fever and delayed leukoencephalopathy following low dose intraventricular methotrexate. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[22]  A. Boddy,et al.  Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  S. Hassenbusch,et al.  Surgery versus radiosurgery in the treatment of brain metastasis. , 1996, Journal of neurosurgery.

[24]  L. Heier,et al.  Detection of brain metastases: comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. , 1990, AJNR. American journal of neuroradiology.

[25]  A. Goldhirsch,et al.  High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  B. de Camargo,et al.  A simple cost-effective lactate dehydrogenase level measurement can stratify patients with Ewing's tumor into low and high risk. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  G. Royle,et al.  Patterns of clinical metastasis in breast cancer: an analysis of 100 patients. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[28]  U. Nestle,et al.  Prognostic factors in brain metastases: should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? , 2000, International journal of radiation oncology, biology, physics.

[29]  F. Khuri,et al.  Paclitaxel/carboplatin chemotherapy as primary treatment of brain metastases in non-small cell lung cancer: a preliminary report. , 1997, Seminars in oncology.

[30]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[31]  E P Frenkel,et al.  Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Front‐line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma , 1999 .

[33]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[34]  S. Seeber,et al.  Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study , 1998, Journal of Cancer Research and Clinical Oncology.

[35]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[36]  G. Barnett,et al.  Results of whole brain radiotherapy in patients with brain metastases from breast cancer: a retrospective study. , 2002, International journal of radiation oncology, biology, physics.

[37]  P. Kosmidis,et al.  Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  W. Woodward,et al.  Cardiovascular death and second non-breast cancer malignancy after postmastectomy radiation and doxorubicin-based chemotherapy. , 2003, International journal of radiation oncology, biology, physics.

[39]  S. Cho,et al.  Causes of death and metastatic patterns in patients with mammary cancer. Ten-year autopsy study. , 1980, American journal of clinical pathology.

[40]  W. Hall,et al.  Brain metastases: Histology, multiplicity, surgery, and survival , 1996 .

[41]  Y. Hagiwara,et al.  Difference in CDDP penetration into CSF between selective intraarterial chemotherapy in patients with malignant glioma and intravenous or intracarotid administration in patients with metastatic brain tumor , 1996, Cancer Chemotherapy and Pharmacology.

[42]  Ronald Brand,et al.  Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery , 1993, Annals of neurology.

[43]  S. Dahrouge,et al.  Response of brain metastases from breast cancer to megestrol acetate: A case report , 2005, Journal of Neuro-Oncology.

[44]  C. Boni,et al.  Combination therapy with platinum and etoposide of brain metastases from breast carcinoma. , 1990, Cancer investigation.

[45]  N. Ruderman,et al.  Use of glucocorticoids in the palliative treatment of metastatic brain tumors , 1965, Cancer.

[46]  L. Deangelis,et al.  Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel , 1995, Cancer.

[47]  W. Wara,et al.  CT characteristics of patients with brain metastases treated in RTOG study 79-16. , 1993, International journal of radiation oncology, biology, physics.

[48]  W R Markesbery,et al.  Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. , 1998, JAMA.

[49]  M. Larsen,et al.  Longterm remission of multiple brain metastases with tamoxifen , 1991, Journal of Neuro-Oncology.

[50]  F. Cappuzzo,et al.  ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases , 2003, British Journal of Cancer.

[51]  E. Larsson,et al.  Brain Metastases — Comparison of Gadodiamide Injection-Enhanced MR Imaging at Standard and High Dose, Contrast-Enhanced CT and Non-Contrast-Enhanced MR Imaging , 1995, Acta radiologica.

[52]  J. Engel,et al.  Determinants and prognoses of locoregional and distant progression in breast cancer. , 2003, International journal of radiation oncology, biology, physics.

[53]  K. Lillehei,et al.  Multiple brain metastases are associated with poor survival in patients treated with surgery and radiotherapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  S. Rodenhuis,et al.  Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study , 2004, Cancer Chemotherapy and Pharmacology.

[55]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[56]  A. Nanji,et al.  Platinum Concentrations in Human Autopsy Tumor Samples , 1988, American journal of clinical oncology.

[57]  L. Grochow,et al.  Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  G. Wampler,et al.  Intracerebral metastases in solid‐tumor patients: Natural history and results of treatment , 1981, Cancer.

[60]  A. Young,et al.  Treatment for patients with cerebral metastases. , 1978, Archives of neurology.

[61]  Christine Solbach,et al.  Identification of high risk breast-cancer patients by gene expression profiling , 2002, The Lancet.

[62]  D. Long,et al.  The response of human cerebral edema to glucosteroid administration , 1966, Neurology.

[63]  W. Lane,et al.  Chemotherapy induces regression of brain metastases in breast carcinoma , 1986, Cancer.

[64]  E. Vokes,et al.  Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  D. D. Maki,et al.  Patterns of disease spread in metastatic breast carcinoma: influence of estrogen and progesterone receptor status. , 2000, AJNR. American journal of neuroradiology.

[66]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[67]  L D Lunsford,et al.  A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. , 1994, International journal of radiation oncology, biology, physics.

[68]  J. Beijnen,et al.  Penetration of Idarubicin into Malignant Brain Tumor Tissue , 1999, Journal of Neuro-Oncology.

[69]  Z. Siddik,et al.  Comparative distribution and excretion of carboplatin and cisplatin in mice , 1988, Cancer Chemotherapy and Pharmacology.

[70]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[71]  D. Kondziolka,et al.  Brain Metastases Treated with Radiosurgery Alone: An Alternative to Whole Brain Radiotherapy? , 2003, Neurosurgery.

[72]  A. Buzdar,et al.  Causes of death in breast cancer a clinicopathologic study , 1980, Cancer.

[73]  A. Buzdar,et al.  Estrogen receptor: A prognostic factor in breast cancer , 1981, Cancer.

[74]  Armin Thron,et al.  Diagnostic Accuracy of MRI Compared to CCT in Patients with Brain Metastases , 2004, Journal of Neuro-Oncology.

[75]  L D Lunsford,et al.  Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. , 1999, International journal of radiation oncology, biology, physics.

[76]  J. Grego,et al.  Predilection of brain metastasis in gray and white matter junction and vascular border zones , 1996, Cancer.

[77]  L. Rutqvist,et al.  Radiation therapy in the management of brain metastases from breast cancer , 2000, Breast Cancer Research and Treatment.

[78]  I. Kaplan,et al.  Stereotaxic radiosurgery for brain metastases: the importance of adjuvant whole brain irradiation. , 1992, International journal of radiation oncology, biology, physics.

[79]  P. Hudgins,et al.  Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. , 1991, AJNR. American journal of neuroradiology.

[80]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  R. Gelber,et al.  The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. , 1980, International journal of radiation oncology, biology, physics.

[82]  D. Horsfall,et al.  Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  M. Namer,et al.  Phase II Study of Oral Idarubicin in Elderly Patients with Advanced Breast Cancer , 1990, American journal of clinical oncology.

[84]  E. Winer,et al.  Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[85]  F. Lohr,et al.  Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  R. Gelber,et al.  Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. , 1981, International journal of radiation oncology, biology, physics.

[87]  M. Melamed,et al.  Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[88]  K Takakura,et al.  Subacute brain atrophy after radiation therapy for malignant brain tumor , 1989, Cancer.

[89]  S. Cherry,et al.  Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. , 1991, European journal of cancer.

[90]  A. Hart,et al.  Brain metastases in breast cancer; natural history, prognostic factors and outcome , 1993, Journal of Neuro-Oncology.

[91]  Yeu‐Tsu N. Lee,et al.  Breast carcinoma: Pattern of metastasis at autopsy , 1983, Journal of surgical oncology.

[92]  L. Recht,et al.  A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[93]  T. Batchelor,et al.  Diagnostic Evaluation of Neurologic Metastases , 2000, Cancer investigation.

[94]  J. Cairncross,et al.  Radation therapy for brain metastases , 1980 .

[95]  P. Lønning,et al.  Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. , 1991, British Journal of Cancer.

[96]  C. Straathof,et al.  The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis , 1999, Journal of Neurology.

[97]  S. Grossman,et al.  The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study , 2004, Cancer Chemotherapy and Pharmacology.

[98]  L Souhami,et al.  Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. , 2000, International journal of radiation oncology, biology, physics.

[99]  A. Howell,et al.  ICI 182,780 (Faslodex™) , 2000, Cancer.

[100]  D. Kondziolka,et al.  Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastases. , 2003, International journal of radiation oncology, biology, physics.

[101]  R. Caprioli,et al.  Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. , 1982, Cancer research.

[102]  J. Manola,et al.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  A. Vincent-Salomon,et al.  Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high‐dose intrathecal methotrexate regimen , 1996, Cancer.

[104]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[105]  A. Young,et al.  Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. , 2002, International journal of radiation oncology, biology, physics.

[106]  R. Demicheli,et al.  Menopausal status dependence of early mortality reduction due to diagnosis of smaller breast cancers (T1 v T2-T3): relevance to screening. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[107]  B. Pestalozzi,et al.  Trastuzumab in CSF. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[109]  G. Hortobagyi,et al.  The natural history of breast cancer patients with brain metastases , 1979, Cancer.

[110]  Y. Iwadate,et al.  Significance of surgical resection for the treatment of multiple brain metastases. , 2000, Anticancer research.

[111]  R. Coleman,et al.  Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. , 2003, Radiology.

[112]  R. Gelber,et al.  The influence of surgery and radiation therapy on patients with brain metastases. , 1983, International journal of radiation oncology, biology, physics.

[113]  M. McDermott,et al.  Number of brain metastases is not an important prognostic factor for survival following radiosurgery for newly-diagnosed nonmelanoma brain metastases , 2003 .

[114]  R. Sawaya,et al.  Surgical treatment of multiple brain metastases. , 1993, Journal of neurosurgery.

[115]  L. Deangelis,et al.  Radiation‐induced dementia in patients cured of brain metastases , 1989, Neurology.

[116]  T. Visakorpi,et al.  Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.

[117]  J. Raizer,et al.  A Phase II Trial of Temozolomide for Patients with Recurrent or Progressive Brain Metastases , 2004, Journal of Neuro-Oncology.

[118]  J. Dawson,et al.  Breast cancer teams: the impact of constitution, new cancer workload, and methods of operation on their effectiveness , 2003, British Journal of Cancer.

[119]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[120]  A. Gregor,et al.  Imaging features of leptomeningeal metastases. , 1999, Clinical radiology.

[121]  D. Kondziolka,et al.  Stereotactic Radiosurgery for Brain Metastases From Breast Cancer , 2000, Annals of Surgical Oncology.

[122]  P. Brown,et al.  Properly Selected Patients with Multiple Brain Metastases May Benefit from Aggressive Treatment of their Intracranial Disease , 2004, Journal of Neuro-Oncology.

[123]  M. Chamberlain,et al.  Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. , 1997, Journal of neurosurgery.

[124]  U. Bogdahn,et al.  Long‐term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin , 2001, Cancer.

[125]  Y. Lee Breast carcinoma: Pattern of recurrence and metastasis after mastectomy , 1984, American journal of clinical oncology.

[126]  M. Mehta,et al.  A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. , 2002, International journal of radiation oncology, biology, physics.

[127]  Yoshiaki Tsukada,et al.  Central nervous system metastasis from breast carcinoma autopsy study , 1983, Cancer.

[128]  M. Mehta,et al.  A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. , 1996, International journal of radiation oncology, biology, physics.

[129]  O. Dalesio,et al.  Response of brain metastases from breast cancer to systemic chemotherapy , 1992, Cancer.

[130]  M. Narabayashi,et al.  Seven cases of breast cancer recurrence limited to the central nervous system without other visceral metastases , 2000, Breast cancer.

[131]  Z. Duan,et al.  Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. , 2003, Current cancer drug targets.

[132]  F. Balis,et al.  Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Temozolomide in Non-human Primates , 2003, Journal of Neuro-Oncology.

[133]  L. Carey,et al.  Disproportionate CNS relapse after aggressive neoadjuvant chemotherapy , 2001 .

[134]  M. Wrónski,et al.  Fractionated Radiosurgery for Brain Metastases in 43 Patients with Breast Carcinoma , 2004, Breast Cancer Research and Treatment.

[135]  A. Hart,et al.  Meningeal carcinomatosis in breast cancer. Prognostic factors and influence of treatment , 1991, Cancer.

[136]  J. Posner,et al.  Headaches in patients with brain tumors , 1993, Neurology.

[137]  K. Possinger,et al.  Oral administration of idarubicin as first line cytostatic therapy in patients with metastasized breast cancer and favourable prognosis. A trial of the phase II study group of the Association for Medical Oncology of the German Cancer Society. , 1991, Onkologie.

[138]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[139]  S. Franco,et al.  A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  M. J. van den Bent,et al.  The effect of dexamethasone on the uptake of cisplatin in 9L glioma and the area of brain around tumor , 1998, Journal of Neuro-Oncology.

[141]  J. O'fallon,et al.  A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. , 2003, International journal of radiation oncology, biology, physics.

[142]  O. Salazar,et al.  Breast Cancer: Metastatic Patterns and Their Prognosis , 1988, Southern medical journal.

[143]  G. Hortobagyi,et al.  Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer , 2000, Cancer Chemotherapy and Pharmacology.

[144]  L. Cervoni,et al.  Prolonged Stabilization of Multiple and Single Brain Metastases from Breast Cancer with Tamoxifen. Report of Three Cases , 1993, Tumori.

[145]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[146]  W. Curran,et al.  Stereotactic radiosurgery with whole brain radiation therapy improves survival in patients with brain metastases: report of radiation therapy oncology group phase III study 95–08 , 2002 .

[147]  N. Robert,et al.  Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  M. E. Jaffe,et al.  The effect of dexamethasone on brain edema in patients with metastatic brain tumors , 1973, Neurology.

[149]  D. Delbeke,et al.  Leptomeningeal Carcinomatosis and Intramedullary Spinal Cord Metastases from Lung Cancer: Detection with FDG Positron Emission Tomography , 2001, Clinical nuclear medicine.

[150]  H. Groen,et al.  Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer. , 1993, European journal of cancer.